Back to Newsroom

Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research

VALENCIA, Calif., Sept. 4, 2013 – Sanguine BioSciences, a biotechnology company enabling personalized medicine research, today announced that it has signed commercial agreements with, and received orders from, more than 200 biomedical researchers at academic, biotechnology and pharmaceutical companies, to enable more efficient personalized medicine research.